Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
101.08
-2.89 (-2.78%)
Jul 23, 2026, 11:22 AM EDT - Market open
Rhythm Pharmaceuticals Employees
Rhythm Pharmaceuticals had 414 employees as of December 31, 2025. The number of employees increased by 131 or 46.29% compared to the previous year.
Employees
414
Change (1Y)
131
Growth (1Y)
46.29%
Revenue / Employee
$524,553
Profits / Employee
-$502,029
Market Cap
6.93B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 414 | 131 | 46.29% |
| Dec 31, 2024 | 283 | 57 | 25.22% |
| Dec 31, 2023 | 226 | 49 | 27.68% |
| Dec 31, 2022 | 177 | 37 | 26.43% |
| Dec 31, 2021 | 140 | 50 | 55.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Mirum Pharmaceuticals | 418 |
| TG Therapeutics | 399 |
| Xenon Pharmaceuticals | 370 |
| Immunovant | 315 |
| Scholar Rock Holding | 289 |
RYTM News
- 2 days ago - Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - GlobeNewsWire
- 14 days ago - Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity - GlobeNewsWire
- 16 days ago - Rhythm Pharmaceuticals price target raised to $141 from $137 at RBC Capital - TheFly
- 5 weeks ago - Rhythm Pharmaceuticals price target raised to $151 from $143 at Canaccord - TheFly
- 5 weeks ago - Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals price target raised to $155 from $144 at Wells Fargo - TheFly
- 5 weeks ago - Rhythm announces preliminary data from Phase 2 trial of setmelanotide - TheFly
- 5 weeks ago - Rhythm Pharmaceuticals Transcript: Study result - Transcripts